Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Fludarabine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 6/20 | 0.82 |
| ▸ | P2RY1 | P47900 | 8/20 | 0.73 |
| ▸ | P2RY11 | Q96G91 | 5/20 | 0.73 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.73 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.73 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.73 |
| ▸ | LDHA | P00338 | 1/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
| ▸ | FBP1 | P09467 | 1/20 | 0.73 |
| ▸ | SRC | P12931 | 1/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.73 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.73 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine Phosphate SCHEMBL14565620 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL3511 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL1650192 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL13046080 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL17541855 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL482449 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL23884975 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL899922 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL21173132 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL30350656 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287510-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20210198707-A1 | METHOD FOR ENZYMATIC PREPARATION OF FLUDARABINE PHOSPHATE | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2021-07-01 | — | — | US | disclosed |
| US-10987372-B2 | Anti-hepatoma-virus agent | KAGOSHIMA UNIVERSITY (JP) | 2021-04-27 | — | — | US | disclosed |
| US-20210085699-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | THE JACKSON LABORATORY (US) | 2021-03-25 | — | — | US | disclosed |
| WO-2020225196-A1 | ANTI-CD19 THERAPY IN PATIENTS HAVING A LIMITED NUMBER OF NK CELLS | MORPHOSYS AG (DE) | 2020-11-12 | — | — | WO | disclosed |
| US-20200352975-A1 | COMBINATIONS AND USES THEREOF | INCYTE CORPORATION | 2020-11-12 | — | — | US | disclosed |
| US-10669302-B2 | Crystal form of fludarabine phosphate, preparation method therefor, and application thereof | ZHEJIANF HISUN PHARMACEUTICAL CO., LTD. (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190195879-A1 | METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS | INCYTE CORPORATION | 2019-06-27 | — | — | US | disclosed |
| US-20190112327-A2 | CRYSTAL FORM OF FLUDARABINE PHOSPHATE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2019-04-18 | — | — | US | disclosed |
| US-20190070207-A1 | ANTI-HEPATOMA-VIRUS AGENT | KAGOSHIMA UNIVERSITY (JP) | 2019-03-07 | — | — | US | disclosed |
| US-9828409-B2 | Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides | ZHONG MINGHONG (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3186237-A1 | HETEROAROMATIC CHALCONE DERIVATIVES AND THEIR MEDICAL USE | Medizinische Universität Wien (AT) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030510-A1 | HETEROAROMATIC CHALCONE DERIVATIVES AND THEIR MEDICAL USE | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2016-03-03 | — | — | WO | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| EP-0686043-B1 | COMPOSITIONS AND METHODS OF APPLICATION OF REACTIVE ANTIVIRAL POLYMERS | WANG JUI H (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0686043-A4 | COMPOSITIONS AND METHODS OF APPLICATION OF REACTIVE ANTIVIRAL POLYMERS | WANG JUI H (US) | 1996-04-17 | — | — | EP | disclosed |
| US-5496546-A | INHIBITORS OF RIBONUCLEASE OF TRANSCRIPTASE | Wang, Jui H. (US) | 1996-03-05 | — | — | US | disclosed |
| EP-0686043-A1 | COMPOSITIONS AND METHODS OF APPLICATION OF REACTIVE ANTIVIRAL POLYMERS | WANG, Jui, H. (US) | 1995-12-13 | — | — | EP | disclosed |
| WO-1994019012-A2 | COMPOSITIONS AND METHODS OF APPLICATION OF REACTIVE ANTIVIRAL POLYMERS | WANG JUI H (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085699-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | RAD51, MRE11, RAD50 | CA5A 311/4885NT5E 2098/4885P2RY1 3833/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | CA5A 130/4885NT5E 1073/4885P2RY1 2284/4885 |
| US-20190112327-A2 | CRYSTAL FORM OF FLUDARABINE PHOSPHATE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, WEE2, TYMP | CA5A 3051/4885NT5E 879/4885P2RY1 750/4885 |
| US-20230287510-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | BCL9, BCL9L, BCL6B | CA5A 2139/4885NT5E 577/4885P2RY1 3797/4885 |
| US-20190195879-A1 | METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS | BCL6B, BCL9L, BCL9 | CA5A 4372/4885NT5E 549/4885P2RY1 4553/4885 |
| US-10987372-B2 | Anti-hepatoma-virus agent | HAVCR2, HDGF, HDGFL3 | CA5A 815/4885NT5E 2698/4885P2RY1 4129/4885 |
| US-20190070207-A1 | ANTI-HEPATOMA-VIRUS AGENT | HAVCR2, HDGF, HDGFL3 | CA5A 815/4885NT5E 2698/4885P2RY1 4129/4885 |
| US-10669302-B2 | Crystal form of fludarabine phosphate, preparation method therefor, and application thereof | WEE1, WEE2, TYMP | CA5A 3051/4885NT5E 879/4885P2RY1 750/4885 |
| US-20200352975-A1 | COMBINATIONS AND USES THEREOF | BCL6B, CD22, BCL6 | CA5A 1386/4885NT5E 54/4885P2RY1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.